Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer
- 15 August 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (16), 5546-5553
- https://doi.org/10.1158/1078-0432.ccr-0943-03
Abstract
Purpose: Decreased expression of E-cadherin in endometrial cancer cells is associated with adverse prognostic features. This study aimed to evaluate the prognostic significance of decreased E-cadherin expression in patients with endometrial cancer. Experimental Design: Between 1992 and 1999, 102 endometrial cancer patients with stage I-III disease underwent primary surgery at the University of Chicago. Representative tissue specimens were immunostained with a monoclonal antibody to E-cadherin. A semiquantitative evaluation scale was developed based on the percentage of endometrial cancer cells with membranous E-cadherin staining. Tissue sections were scored as “3” if >75%, “2” if 25–75%, “1” if 5–25%, and “0” if Results: E-Cadherin staining was scored as 0, 1, 2, and 3 in 29.4%, 18.6%, 26.5%, 25.5% of cases, respectively. E-Cadherin expression was positively correlated with myometrial invasion (Kendall τ: 0.30, P < 0.01), and negatively correlated with grade (Kendall τ: −0.13, P = 0.15) and papillary serous or clear cell histology (Kendall τ: −0.14, P = 0.12). Five-year actuarial OS, CSS, PFS, and extrapelvic recurrence rates for negative (score = 0), heterogeneous (score = 1–2), and positive (score = 3) staining were as follows: OS, 69.2 versus 75.7 versus 81.0% (P = 0.64); CSS, 78.8 versus 91.2 versus 95.5% (P = 0.19); PFS, 69.1 versus 88.6 versus 92.2% (P = 0.079), and extrapelvic progression, 20.8 versus 7.3 versus 4.0% (P = 0.17). On multivariate Cox regression, a higher E-cadherin expression score was associated with decreased overall mortality [hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.34–1.03; P = 0.066), and statistically significant decreases in endometrial cancer mortality (HR, 0.23; 95% CI, 0.055–0.94; P = 0.040), disease progression (HR, 0.28; 95% CI, 0.10–0.77; P = 0.014), and extrapelvic recurrence (HR, 0.24; 95% CI, 0.062–0.97; P = 0.045). Conclusions: Decreased E-cadherin expression is an independent prognostic factor for disease progression and mortality in pathological stage I-III endometrial cancer. Evaluation of E-cadherin expression may aid in the selection of patients for more aggressive adjuvant therapy.Keywords
This publication has 52 references indexed in Scilit:
- Hypermethylation in promoter region of E‐cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinomaCancer, 2003
- Cyclooxygenase‐2 expression in endometrial carcinomaCancer, 2002
- Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancerInternational Journal of Gynecologic Cancer, 2002
- Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinomaCancer, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Stage III Endometrial Cancer: Analysis of Prognostic Factors and Failure Patterns after Adjuvant ChemotherapyGynecologic Oncology, 2001
- Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of Stage I endometrial carcinomaCancer, 1999
- Prognostic Significance of DNA Ploidy in Endometrial CancerGynecologic Oncology, 1999
- Postoperative Adjuvant Cisplatin, Doxorubicin, and Cyclophosphamide (PAC) Chemotherapy in Women with High-Risk Endometrial CarcinomaGynecologic Oncology, 1994
- Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor roleCell, 1991